Find the latest pharmaceutical market place for formulations enquiry about Darifenacin Hydrobromide on PharmaCompass.com.

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations in China [ENA00365]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners for its US FILED Products for the Chinese Market:

Products developed against international innovator:
1. Gliclazide 30/60 mg ER Tablets
2. Metformin HCl 500/750/1000 mg SR Tablets.
3. Lansoprazole 15/30 mg EC Capsules
4. Metoprolol 25/50/100/200 mg ER Tablets
5. Olmesartan Medoxomil 5/20/40 mg Tablets
6. Telmisartan 20/40/80 mg Tablets
7. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
8. Duloxetine 20/30/60 mg DR Capsules
9. Venlafaxine 37.5/75/150 mg SR Capsules
10. Darifenacin Hydrobromide 7.5/15 mg ER Tablets
11. Felodipine 2.5/5/10 mg ER Tablets
12. Rosuvastatin 5 /10/20/40 mg Tablets
13. Iloperidone 1/2/4/6/8/10/12 mg Tablets
14. Paliperidone 1.5/3/6/9 mg ER Tablets
15. Tolterodine Tartrate 2/4 mg ER Capsules

New Products Under development
1. Sitagliptin + Metformin 50/500 mg, 50/1000 mg Tablets
2. Sitagliptin + Metformin ER 50/500 mg, 50/1000; 100/1000 mg Tablets
3. Dapagliflozin 5/10 mg Tablets
4. Mesalamine 1.2 mg DR Tablets
5. Ezetimibe 10 mg Tablets
Interested partners can contact Sumeet Mehta at sumeet.mehta@inventiahealthcare.com or call +91-9930922062.

Reply

12 Jun 2017

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations across Emerging Markets [ENA00236...

Inventia Healthcare, is searching for partners for:
DEVELOPED PRODUCTS
South East Asia, CIS, Australia, Middle East & Africa, LATAM:-
1. Lansoprazole 15/30 mg EC Capsules
2. Metoprolol 25/50/100/200 mg ER Tablets
3. Olmesartan Medoxomil 5, 20, 40 mg Tablets
4. Telmisartan 20/40/80 mg Tablets
5. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
6. Duloxetine 20/30/60 mg DR Capsules
7. Venlafaxine 37.5/75/150 mg SR Capsules
8. Darifenacin Hydrobromide 7.5/15 mg ER Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM Argentina, Uruguay, Paraguay, Chile:-
1. Metformin HCl 750 mg SR Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM, India:-
1. Gliclazide 30/60 mg ER Tablets
2. Felodipine 2.5/5/10 mg ER Tablets
3. Rosuvastatin 5 /10 /20/40 mg Tablets

Dossier for South East Asia, CIS, Australia Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Middle East & Africa, South Africa, GCC, Iraq, Algeria, LATAM, Argentina, Uruguay, Paraguay, Chile, India:-
1. Metformin HCl 500 mg SR Tablets

Dossier for South East Asia, CIS, Australia, Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Malaysia, LATAM, Argentina, Uruguay, Paraguay, Chile, All countries in SEA, CIS, Australia, Middle East & Africa:-
1. Metformin HCl 1000 mg SR Tablets
Interested partners can contact @ https://www.pharmacompass.com/api-manufacturers/inventia-healthcare-private-limited

Reply

02 Mar 2017

EU CTD Dossiers Available // Looking for Marketing Partners in the EU for various products [ENA00142]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners in Europe for the following products which are at various stages of development -

Approved MA:
1. Duloxetine DR Capsules 30 mg/ 60 mg

Products Under development:
1. Gliclazide MR Tablets 30 mg/ 60 mg - EU fillable dossier will be ready by Oct 2017
2. Ezetimibe 10 mg Tablets - EU fillable dossier will be ready by Dec 2017

Products developed against international innovators and easily extendable to EU
1. Metformin SR Tablets 500 mg
2. Metformin SR Tablets 750 mg
3. Metformin SR Tablets 1000 mg
4. Darifenacin ER tablets 7.5 mg/ 15 mg

New Products Under development for EU
1. Rivaroxaban Tablets 10mg, 15 mg, 20 mg: will be ready by Q3 2019
2. Sitagliptin + Metformin: Target to be ready by Q2 2022
3. Mesalamine 1200 Gm Tablets - Target to be ready by Q3 2019

Interested partners should contact Priyanka Dhanjal at priyanka.dhanjal@inventiahealthcare.com or call +919987152274

Reply

02 Jan 2017

Enquiry//eCTD Dossiers required for various products [ENA00027]

Bilcare, a reliable and credible long-term partner of the global pharmaceutical industry for Clinical Trial Material Supplies has received requests for the following products -
1. Colesevalam tablets 625 mg for US market.
2. Nitrofurantoin capsules 50/ 100mg for UK, South Africa, Italy and Croatia markets
3. Cetirizine tablets 20 mg for Canada /Us/EU market
4. Colchicine tablets 0.5 mg for UK market
5. Carbimazole tablets 5 & 20 mg for UK market
6. Tolterodine ER capsule 2/4 mg for US market
7. Sevelamer Carbonate tablets 800 mg for US market
8. Sevelamer suspension for US
9. Carbidopa tablets for EU.
10. Azithromycin 250 mg capsules for EU
11. Mesalamine 1200 mg tabs for EU
12. Mesalazine 400 mg and 800 mg for EU
13. Alimemazine 10mg tab for EU
14. Hydrocortisone 10 mg tab for EU
15. Diclofenac sod.3%, sodium hyaluronate 2.5% (Solaraze) for EU
16. Ciprofibrate 100 mg tab for EU
17. Hydroxy urea capsules for US/EU
18. Tamoxifen citrate tabs for US/EU
19. Gefitinib tabs for US/EU
20. Sunitinib capsules for US/EU
21. Lacosamide for EU
22. Aripiprazole tabs for US
23. Darifenacin ER for US
24. Memantine tablets 5/10mg, Oral solution 2mg/ml, ER capsules 7/14/21/28mg for US,
25. Memantine ER + Donepezil capsules 14mg+10mg/ 28mg+10mg for US

Interested companies should respond immediately to Chhanda Das, VP-QA and Regulatory, Bilcare Limited at Chhanda.Das_GCS@bilcare.com.

Reply

04 Jul 2016